The initial investigation of the change of myeloid dendritic cells level in ankylosing spondylitis after treatment with TNF-α blocker
10.3760/cma.j.issn.1007-7480.2010.05.002
- VernacularTitle:强直性脊柱炎患者抗肿瘤坏死因子-α治疗前后外周血髓系树突状细胞变化的初步研究
- Author:
Huiqin HAO
;
Feng HUANG
;
Liping PANG
;
Lisha WANG
;
Yamei ZHANG
;
Jie TANG
;
Xianfeng FANG
- Publication Type:Journal Article
- Keywords:
Spondylitis,ankylosing;
Tumour necrosis factor;
Dendritic cells
- From:
Chinese Journal of Rheumatology
2010;14(5):293-296
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the role of myeloid dendritic cells(mDC)in the pathogenesis of ankylosing spondylitis (AS),and to study the mechanism of tumour necrosis factor (TNF)-α blocker on the treatment of AS by counting the number of mDC before and after the treatment.Methods Peripheral blood from 21 AS patients treated with 50 mg rhTNFR-Fc and 15 AS patients treated with placebo were investigated at week 0,week 2 and week 6 in a randomized,double-blind,placebo-controlled trial.Three-color flow cytometry analysis was used to investigate the change of the number of mDC before and after the treatment.And their correlation with the clinical parameters was analyzed.Results MHC Class Ⅰ positive mDC(Lin-/CD11c+/HLA-abc+)in AS patients was slightly less than in healthy controls (not statistically significant).No significant change in MHC Class Ⅰ mDC number was observed after drug treatment.The number of MHC Class Ⅱ mDC cells was not correlated with clinical parameters.Conclusion The treatment with rhTNFR-Fc in AS induces a significant upregnlation of MHC-Ⅱ DC.
